• Explore /
  • Poster
  • / A multicohort phase II study of durvalumab plus tremelimumab for the treatment of patients (PTS) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or lung origin (the DUNE trial-GETNE1601-).

A multicohort phase II study of durvalumab plus tremelimumab for the treatment of patients (PTS) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or lung origin (the DUNE trial-GETNE1601-).

Abstract Poster

Authors

null

Ignacio Matos Garcia

Vall d’Hebron University Hospital Institute of Oncology (VHIO), Barcelona, Spain

Ignacio Matos Garcia , Enrique Grande , Rocio Garcia-Carbonero , Carlos Lopez , Alexandre Teule , Jaume Capdevila

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Neuroendocrine/Carcinoid

Clinical Trial Registration Number

2016-002858-20

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS4146)

DOI

10.1200/JCO.2017.35.15_suppl.TPS4146

Abstract #

TPS4146

Poster Bd #

130b

Abstract Disclosures

Similar Posters

First Author: David Tougeron

First Author: Jun Ni

First Author: Matthieu Delaye

First Author: Ho Yeong Lim